This object is in collection
Abstract: Canagliflozin, a sodium-glucose transport protein 2 (SGLT2)
inhibitor, is a novel drug used to treat type 2 diabetes mellitus (T2DM). A phase II
glucuronide conjugation reaction is the primary elimination pathway of canagliflozin.
Uridine diphosphate glucuronosyltransferases (UGTs) are the responsible enzymes for the
glucuronidation reactions that occur in phase II metabolism. The gl... read more